Astellas invests $10M in Cytori; Geron plots $87M stock sale; StemCells gets green light for PhaseI/II

 @FierceBiotech:  Orexigen braces for advisory panel's Contrave review. Article | Follow @FierceBiotech

 @JohnCFierce: The panel vote favoring Allergan's lap band and the trouble Orexigen faces on risk factors underscores basic distrust of drugs for obesity. Follow @JohnCFierce

> Geron says it plans to raise $87 million in a stock sale. Report

> Astellas Pharma will invest $10 million in Cytori as it evaluates the biotech's stem cell technology. Shares of Cytori surged on news of the deal. Story

> Swiss officials have signed off on StemCells Phase I/II trial of purified human neural stem cells for chronic spinal damage. StemCells release

> Immunomedics, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that epratuzumab, the company's humanized anti-CD22 antibody, conjugated with SN-38, the active component of irinotecan, produced significant anti-tumor responses in a mouse model of human lymphoma. Immunomedics release

And Finally... Researchers say that the DRD4 gene, already linked to alcohol use and gambling, could also play a role in spurring a propensity for brief sexual liaisons. Story

Suggested Articles

A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.